Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Survival will out

Dendreon Corp. had its sights set on obtaining approval of its Provenge immunotherapy to treat only those prostate cancer patients with Gleason scores of 7 or less after the compound missed the primary endpoint in a broader patient population in the company's first Phase III trial. But 36-month survival data from the trial

Read the full 537 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers